GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » Debt-to-EBITDA

Jacobio Pharmaceuticals Group Co (HKSE:01167) Debt-to-EBITDA : -0.56 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jacobio Pharmaceuticals Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$96.19 Mil. Jacobio Pharmaceuticals Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$133.41 Mil. Jacobio Pharmaceuticals Group Co's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-411.91 Mil. Jacobio Pharmaceuticals Group Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.56.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:01167' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.64   Med: -0.08   Max: -0.01
Current: -0.6

During the past 6 years, the highest Debt-to-EBITDA Ratio of Jacobio Pharmaceuticals Group Co was -0.01. The lowest was -0.64. And the median was -0.08.

HKSE:01167's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs HKSE:01167: -0.60

Jacobio Pharmaceuticals Group Co Debt-to-EBITDA Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co Debt-to-EBITDA Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.05 -0.01 -0.02 -0.42 -0.64

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.31 -0.63 -0.56

Competitive Comparison of Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA falls into.



Jacobio Pharmaceuticals Group Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(96.192 + 133.407) / -356.273
=-0.64

Jacobio Pharmaceuticals Group Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(96.192 + 133.407) / -411.91
=-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Jacobio Pharmaceuticals Group Co  (HKSE:01167) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Jacobio Pharmaceuticals Group Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobio Pharmaceuticals Group Co (HKSE:01167) Business Description

Traded in Other Exchanges
Address
No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.
Executives
Shen Zhu 2501 Other
Treasure Partner International Limited 2501 Other
Ultimate Estate Limited 2201 Interest of corporation controlled by you
Wang Yinxiang 2501 Other
Wang Xiaojie 2307 Founder of a discretionary trust who can infl
Hu Yunyan 2501 Other
Yakovpharma Ltd 2501 Other
Willgenpharma Ltd 2501 Other
Risepharma Ltd 2101 Beneficial owner
Johwpharma Ltd 2501 Other
Hmed Ltd 2501 Other
Gloryviewpharma Ltd 2501 Other
Honourpharma Ltd 2501 Other
Blesspharma Ltd 2501 Other
Hillhouse Investment Management, Ltd. 2102 Investment manager

Jacobio Pharmaceuticals Group Co (HKSE:01167) Headlines

No Headlines